Inspection Record

RC Compounding Services, LLC — FDA 483 Findings

US FDAInspected 2018-03-16Published 2024-01-17 6 findingsAseptic processing and sterility assuranceTraining and personnelContamination controlEquipment and facility

Inspectors Matthew B Casale · Jazmine N StillThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Non-sterilized and Non-depyrogenated equipment was used in sterile drug production.

2Aseptic processing and sterility assurance

Personnel placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

3Aseptic processing and sterility assurance

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

4Training and personnel

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

5Contamination control

You produced highly potent drugs without providing adequate containment, cleaning of work surfaces and cleaning of personnel to prevent cross-contamination.

6Equipment and facility

Your facility design allowed the influx of poor quality air into a higher classified area.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

RC Compounding Services, LLC company profile — full history US FDA documents, 2024 Go to Findings search